PMID- 19531101
OWN - NLM
STAT- MEDLINE
DCOM- 20091211
LR  - 20151119
IS  - 1399-0039 (Electronic)
IS  - 0001-2815 (Linking)
VI  - 74
IP  - 3
DP  - 2009 Sep
TI  - Characterization of HLA-G expression in renal cell carcinoma.
PG  - 213-21
LID - 10.1111/j.1399-0039.2009.01302.x [doi]
AB  - Previous studies showed that human leukocyte antigen (HLA)-G is specifically 
      upregulated in renal cell carcinoma (RCC). However, a larger cohort of RCC 
      patients are necessary to obtain more information. In this study, 109 RCC primary 
      lesions (clear cell, n = 95; chromophobe, n = 4; papillary, n = 4; collecting 
      duct, n = 6) and corresponding adjacent tumor-negative renal tissues (n = 34) 
      were analyzed for the HLA-G expression by immunohistochemistry (IHC). Meanwhile, 
      plasma soluble HLA-G (sHLA-G) from 16 RCC patients and 144 sex- and age-matched 
      normal individuals was detected by enzyme-linked immunosorbent assay. 
      Correlations between lesion HLA-G expression and various clinical parameters were 
      evaluated. Receiver-operating characteristic (ROC) curve analysis was used to 
      determine the feasibility of HLA-G protein staining and sHLA-G as a diagnosis 
      marker for RCC. IHC data showed that HLA-G was observed in 49.5% of clear cell, 
      50% of either chromophobe or collecting duct RCC lesions but undetectable in 
      papillary RCC and tumor-negative renal tissues. This finding was consistent with 
      the western blot results. sHLA-G was pronouncedly increased in RCC patients when 
      compared with normal controls (median: 39.5 vs 19.2 U/ml, P = 0.002). However, no 
      correlation was observed between HLA-G expression and various clinical 
      parameters. We found that the area under ROC curve for HLA-G expression and 
      sHLA-G was 0.739 [95% confidence interval (95% CI): 0.659-0.816, P = 0.000] and 
      0.733 (95% CI: 0.619-0.847, P = 0.002), respectively. Our findings indicated 
      that, except the papillary RCC, other types of RCC could express HLA-G. 
      Furthermore, both lesion HLA-G expression and plasma sHLA-G level might be a 
      useful preoperative biomarker for diagnosis.
FAU - Li, B-L
AU  - Li BL
AD  - Medical Research Center, Taizhou Hospital of Zhejiang Province, Wenzhou Medical 
      College, Linhai, Zhejiang, China.
FAU - Lin, A
AU  - Lin A
FAU - Zhang, X-J
AU  - Zhang XJ
FAU - Zhang, X
AU  - Zhang X
FAU - Zhang, J-G
AU  - Zhang JG
FAU - Wang, Q
AU  - Wang Q
FAU - Zhou, W-J
AU  - Zhou WJ
FAU - Chen, H-X
AU  - Chen HX
FAU - Wang, T-J
AU  - Wang TJ
FAU - Yan, W-H
AU  - Yan WH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090615
PL  - England
TA  - Tissue Antigens
JT  - Tissue antigens
JID - 0331072
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-G Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
SB  - IM
MH  - Age Distribution
MH  - Biomarkers, Tumor/*immunology
MH  - Carcinoma, Renal Cell/genetics/*immunology/pathology
MH  - Case-Control Studies
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Feasibility Studies
MH  - Female
MH  - *Gene Expression
MH  - HLA Antigens/*immunology
MH  - HLA-G Antigens
MH  - Histocompatibility Antigens Class I/analysis/*immunology
MH  - Histocompatibility Antigens Class II/genetics/immunology
MH  - Humans
MH  - Immunohistochemistry
MH  - Kidney Neoplasms/genetics/*immunology/pathology
MH  - Male
MH  - Middle Aged
MH  - ROC Curve
MH  - Solubility
EDAT- 2009/06/18 09:00
MHDA- 2009/12/16 06:00
CRDT- 2009/06/18 09:00
PHST- 2009/06/18 09:00 [entrez]
PHST- 2009/06/18 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - TAN1302 [pii]
AID - 10.1111/j.1399-0039.2009.01302.x [doi]
PST - ppublish
SO  - Tissue Antigens. 2009 Sep;74(3):213-21. doi: 10.1111/j.1399-0039.2009.01302.x. 
      Epub 2009 Jun 15.